Cincor Pharma Inc (CINC) PT Raised to $60 at Morgan Stanley
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/5/2026
- Nasdaq eyes lower open after midterms-fueled surge as chip, data center stocks fall
- Massive market rotation raises question: Is the sell-AI trade here to stay?
- Goldman sees major AI and data center policy implications from ‘blue tsunami’
- Nvidia chips stockpile in Hong Kong awaits China import approval - report
- Goldman says this FX trade is the best hedge for the AI drawdown
Tweet
Share
E-mailGet Alerts CINC Hot Sheet
Price: $29.06 --0%
Rating Summary:
4 Buy, 3 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 20 | Down: 36 | New: 6
Rating Summary:
4 Buy, 3 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 20 | Down: 36 | New: 6
Join SI Premium – FREE
Morgan Stanley analyst Jeffrey Hung raised the price target on Cincor Pharma Inc (NASDAQ: CINC) to $60.00 (from $45.00) while maintaining a Overweight rating.
You May Also Be Interested In
- North American Construction Group (NOA:CN) (NOA) PT Lowered to Cdn$20 at BMO Capital
- Jack Henry (JKHY) PT Raised to $185 at UBS
- SolarEdge (SEDG) PT Lowered to $29 at Morgan Stanley
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
